Titre : Vincristine

Vincristine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Communication

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment la vincristine est-elle utilisée dans le diagnostic ?

La vincristine n'est pas un outil de diagnostic, mais un traitement pour des cancers diagnostiqués.
Vincristine Cancer Diagnostic
#2

Quels tests précèdent l'administration de vincristine ?

Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie.
Tests de laboratoire Imagerie médicale Vincristine

Symptômes 2

#1

Quels sont les effets secondaires de la vincristine ?

Les effets secondaires incluent neuropathie, constipation, et fatigue.
Effets secondaires Neuropathie Vincristine
#2

La vincristine cause-t-elle des douleurs ?

Oui, elle peut provoquer des douleurs neuropathiques chez certains patients.
Douleur Neuropathie Vincristine

Prévention 2

#1

Peut-on prévenir les effets secondaires de la vincristine ?

Des mesures préventives incluent une surveillance étroite et des médicaments pour les symptômes.
Prévention Effets secondaires Vincristine
#2

Y a-t-il des recommandations avant le traitement par vincristine ?

Oui, une évaluation médicale complète est recommandée avant le traitement.
Évaluation médicale Vincristine Préparation au traitement

Traitements 2

#1

Avec quels médicaments la vincristine est-elle souvent combinée ?

Elle est souvent combinée avec la prednisone et d'autres agents chimiothérapeutiques.
Chimiothérapie Vincristine Prednisone
#2

Comment la vincristine est-elle administrée ?

La vincristine est administrée par voie intraveineuse, généralement en cycle.
Administration intraveineuse Vincristine Chimiothérapie

Complications 2

#1

Quelles complications peuvent survenir avec la vincristine ?

Des complications incluent des infections, des troubles neurologiques et des problèmes gastro-intestinaux.
Complications Infections Vincristine
#2

La vincristine peut-elle causer des problèmes cardiaques ?

Bien que rare, des problèmes cardiaques peuvent survenir, nécessitant une surveillance.
Problèmes cardiaques Vincristine Surveillance médicale

Facteurs de risque 2

#1

Qui est à risque d'effets indésirables de la vincristine ?

Les patients âgés et ceux avec des antécédents de neuropathie sont à risque accru.
Facteurs de risque Neuropathie Vincristine
#2

Les antécédents médicaux influencent-ils le traitement par vincristine ?

Oui, des antécédents de maladies neurologiques peuvent affecter le traitement.
Antécédents médicaux Vincristine Neurologie
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vincristine : Questions médicales les plus fréquentes", "headline": "Vincristine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vincristine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-27", "dateModified": "2025-02-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vincristine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alcaloïdes de Vinca", "url": "https://questionsmedicales.fr/mesh/D014748", "about": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca", "code": { "@type": "MedicalCode", "code": "D014748", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827" } } }, "about": { "@type": "MedicalCondition", "name": "Vincristine", "alternateName": "Vincristine", "code": { "@type": "MedicalCode", "code": "D014750", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wenjian Yang", "url": "https://questionsmedicales.fr/author/Wenjian%20Yang", "affiliation": { "@type": "Organization", "name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Deqing Pei", "url": "https://questionsmedicales.fr/author/Deqing%20Pei", "affiliation": { "@type": "Organization", "name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Cheng Cheng", "url": "https://questionsmedicales.fr/author/Cheng%20Cheng", "affiliation": { "@type": "Organization", "name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "William E Evans", "url": "https://questionsmedicales.fr/author/William%20E%20Evans", "affiliation": { "@type": "Organization", "name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Richard H Ho", "url": "https://questionsmedicales.fr/author/Richard%20H%20Ho", "affiliation": { "@type": "Organization", "name": "Vanderbilt University Medical Center, Nashville, TN." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Communication Overload in Hospitals: Exploring Organizational Safety Communication, Worker Job Attitudes, and Communication Efficacy.", "datePublished": "2022-09-29", "url": "https://questionsmedicales.fr/article/36172847", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/10410236.2022.2129313" } }, { "@type": "ScholarlyArticle", "name": "Strategic communication as planned behavior for science and risk communication: A theory-based approach to studying communicator choice.", "datePublished": "2022-09-18", "url": "https://questionsmedicales.fr/article/36116781", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/risa.14029" } }, { "@type": "ScholarlyArticle", "name": "Communication Openings: A Novel Approach for Serious Illness Communication in Homecare.", "datePublished": "2023-11-01", "url": "https://questionsmedicales.fr/article/37906048", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3928/00989134-20231011-02" } }, { "@type": "ScholarlyArticle", "name": "Everyday Barriers in Communicative Participation According to People With Communication Problems.", "datePublished": "2023-02-14", "url": "https://questionsmedicales.fr/article/36787154", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1044/2022_JSLHR-22-00405" } }, { "@type": "ScholarlyArticle", "name": "Beyond dyadic communication: Network of communication in inflammatory arthritis teams.", "datePublished": "2022-05-29", "url": "https://questionsmedicales.fr/article/35635126", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/17423953221102629" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indolizine", "item": "https://questionsmedicales.fr/mesh/D007212" }, { "@type": "ListItem", "position": 6, "name": "Indolizidines", "item": "https://questionsmedicales.fr/mesh/D054836" }, { "@type": "ListItem", "position": 7, "name": "Alcaloïdes indoliques", "item": "https://questionsmedicales.fr/mesh/D026121" }, { "@type": "ListItem", "position": 8, "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "item": "https://questionsmedicales.fr/mesh/D046948" }, { "@type": "ListItem", "position": 9, "name": "Alcaloïdes de Vinca", "item": "https://questionsmedicales.fr/mesh/D014748" }, { "@type": "ListItem", "position": 10, "name": "Vincristine", "item": "https://questionsmedicales.fr/mesh/D014750" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vincristine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vincristine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vincristine", "description": "Comment la vincristine est-elle utilisée dans le diagnostic ?\nQuels tests précèdent l'administration de vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Communication#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vincristine", "description": "Quels sont les effets secondaires de la vincristine ?\nLa vincristine cause-t-elle des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Communication#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vincristine", "description": "Peut-on prévenir les effets secondaires de la vincristine ?\nY a-t-il des recommandations avant le traitement par vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Communication#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vincristine", "description": "Avec quels médicaments la vincristine est-elle souvent combinée ?\nComment la vincristine est-elle administrée ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Communication#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vincristine", "description": "Quelles complications peuvent survenir avec la vincristine ?\nLa vincristine peut-elle causer des problèmes cardiaques ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Communication#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vincristine", "description": "Qui est à risque d'effets indésirables de la vincristine ?\nLes antécédents médicaux influencent-ils le traitement par vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Communication#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la vincristine est-elle utilisée dans le diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La vincristine n'est pas un outil de diagnostic, mais un traitement pour des cancers diagnostiqués." } }, { "@type": "Question", "name": "Quels tests précèdent l'administration de vincristine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie." } }, { "@type": "Question", "name": "Quels sont les effets secondaires de la vincristine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent neuropathie, constipation, et fatigue." } }, { "@type": "Question", "name": "La vincristine cause-t-elle des douleurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des douleurs neuropathiques chez certains patients." } }, { "@type": "Question", "name": "Peut-on prévenir les effets secondaires de la vincristine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures préventives incluent une surveillance étroite et des médicaments pour les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des recommandations avant le traitement par vincristine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une évaluation médicale complète est recommandée avant le traitement." } }, { "@type": "Question", "name": "Avec quels médicaments la vincristine est-elle souvent combinée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle est souvent combinée avec la prednisone et d'autres agents chimiothérapeutiques." } }, { "@type": "Question", "name": "Comment la vincristine est-elle administrée ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La vincristine est administrée par voie intraveineuse, généralement en cycle." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la vincristine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections, des troubles neurologiques et des problèmes gastro-intestinaux." } }, { "@type": "Question", "name": "La vincristine peut-elle causer des problèmes cardiaques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Bien que rare, des problèmes cardiaques peuvent survenir, nécessitant une surveillance." } }, { "@type": "Question", "name": "Qui est à risque d'effets indésirables de la vincristine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les patients âgés et ceux avec des antécédents de neuropathie sont à risque accru." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le traitement par vincristine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies neurologiques peuvent affecter le traitement." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 21/02/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Wenjian Yang

3 publications dans cette catégorie

Affiliations :
  • Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Deqing Pei

3 publications dans cette catégorie

Affiliations :
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Cheng Cheng

3 publications dans cette catégorie

Affiliations :
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

William E Evans

3 publications dans cette catégorie

Affiliations :
  • Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Richard H Ho

3 publications dans cette catégorie

Affiliations :
  • Vanderbilt University Medical Center, Nashville, TN.

Sima Jeha

2 publications dans cette catégorie

Affiliations :
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Ching-Hon Pui

2 publications dans cette catégorie

Affiliations :
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Mirjam E van de Velde

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Aniek Uittenboogaard

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Gertjan J L Kaspers

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Esperanza Herradón

2 publications dans cette catégorie

Affiliations :
  • Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
  • Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
  • High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :

Visitación López-Miranda

2 publications dans cette catégorie

Affiliations :
  • Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
  • Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
  • High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :

Yang Li

2 publications dans cette catégorie

Affiliations :
  • Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, PR China.

Jing Huang

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Mental Health Institute of the Second Xiangya Hospital, Central South University, Chinese National Clinical Research Center on Mental Disorders (xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China.
Publications dans "Vincristine" :

Johnny Donovan

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Zicheng Deng

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.
  • Center for Lung Regenerative Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Fenghua Bian

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Samriddhi Shukla

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Jose Gomez-Arroyo

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • Division of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States.

Donglu Shi

2 publications dans cette catégorie

Affiliations :
  • The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.

Sources (10000 au total)

Everyday Barriers in Communicative Participation According to People With Communication Problems.

The purpose of this study was to gain a comprehensive understanding of participation situations that are challenging for people with communication problems, to provide input for the further developmen... A purposive sampling strategy was used to include a diverse group of people with communication problems. Diaries were used as a sensitizing exercise for inductive in-depth interviews. In these intervi... Eighteen interviews yielded 44 different concepts. They were clustered in six themes, which capture the person, location, topic, mode, moment, and pace of communication. In total, 103 new items measur... This study resulted in an overview of self-reported barriers in daily communicative participation experienced by people with communication problems. These communicative participation situations can be...

Beyond dyadic communication: Network of communication in inflammatory arthritis teams.

To explore how communication is perceived and care is negotiated amongst IA healthcare teams by drawing on the perspectives of each team member.... This analysis drew on data from an ongoing three-year study exploring team-based IA care. We interviewed 11 participants including two men with IA and their family care providers and healthcare provid... Analysis revealed three themes regarding communication and care: (1) seeking/sharing information, (2) striving to coordinate unified care, and (3) providing patients a voice.... This study emphasizes the importance of understanding team dynamics beyond the dyad of patient and care provider. Negotiating power and decision-making in IA care is a dynamic process involving shifti...

Changes in the communicative skills of young people as a result of a communication training.

To analyze the effect of communication training developed for adolescents on the youth's communication skills.... Forty-one young people participated in the study and were divided into two groups. Group I received intervention - communication training for five weeks; Group II - were guided on the importance of vo... The analysis of questionnaires showed improvement in GI in two of the four skills assessed and no difference for GII. The video evaluations showed a significant difference between the groups in terms ... This study points out that the communication training method applied to young people might improve communicative skills, providing some insights into their communication strengths and potential areas ...

Effects of Aided Communication on Communicative Participation for People With Amyotrophic Lateral Sclerosis.

Many people with amyotrophic lateral sclerosis (PALS) experience speech changes, which may interfere with participation in communication situations. This study was designed to investigate the effects ... Participants with amyotrophic lateral sclerosis completed an online questionnaire in which they identified their current communication methods, rated their speech function, and rated their communicati... Communication aids appeared to support communicative participation for many participants with dysarthria. Across all levels of speech function, PALS who use aided communication reported better partici... Aided communication can help PALS continue to participate in various communication situations as their speech function deteriorates. Variability in self-rated communicative participation, even for PAL... https://doi.org/10.23641/asha.22782986....

Communication experiences of healthcare students whilst managing adults with communication disorders.

Research has found that people with communication disabilities are three times more likely to encounter medical mishaps. Almost a third of patients with speech-language therapy (SLT) diagnoses have ot... This study aims to describe the communication challenges and strategies employed by a group of final year Nursing, Medicine, Dietetics and Human Nutrition, Physiotherapy and Occupational Therapy stude... A qualitative, phenomenological study design was used. Questionnaires were electronically distributed, and results were analysed thematically.... The most significant challenges whilst managing adults with communication disorders were patients' receptive and expressive language difficulties. Further challenges included lack of knowledge surroun... This study revealed that there is a need to develop healthcare students' skills in managing adults with communication disorders. This is because of the challenges faced and inefficiency of the strateg...